London, UK 4 October 2006
Intersuisse BioScience Managers and its co-sponsors are pleased to announce
that Martin Greenacre, former executive chairman of SmithKline Beecham Europe
and now Chairman of Beijing Med-Pharm, will be the special guest speaker at
the 3rd Asia Pacific Life Science Forum to be held at the Cumberland Hotel,
London on October 12, 2006.
Martin Greenacre will speak on commercial strategies for
developing pharmaceutical markets in China - soon to be the world's largest
consumer market - and how to access the development capital for such
strategies.
The Asia Pacific region is increasingly looking to the life
sciences to drive local economies and address local medical and agricultural
needs. Australia has a pedigree in medical devices and at least two global
successes with Biota and Peptech; Korea has a burgeoning generics industry,
and Singapore is blazing a trail in stem cell research.
Attendance at the Forum is limited so please apply as soon as
possible to receive a complimentary place. There will be an Australian
wine-tasting and reception at the end of the day and an opportunity to mingle
with senior management of 15 Asian and Australian quoted companies and both
private equity and public market investors.
Enquiries: Fiona Brown at
conference@biosciencemanagers.com
For more information about the forum
The third investment showcase of leading Australian and Asia
Pacific growth companies in Life Sciences will take place on 12 October, 2006
at the Cumberland Hotel, Marble Arch, London W1. This unique forum brings to
an invited London investment audience 20 mid-stage companies from Australia
and Asian countries. The forum is hosted by Intersuisse Bioscience Managers,
UK/Australia, Northbank Communications and Rodman & Renshaw Elixir Securities.
Companies presenting: Australian biotechs Agenix Limited (ASX:AGX),
Peptech Limited (ASX:PTD), Bionomics Limited (ASX:BNO, US OTC:BMICY), Biota
Holdings (ASX:BTA), Uscom (ASX:UCM), Medical Therapies (ASX:MTY), Proteome
Systems (ASX:PTL), Starpharma (ASX:SPL), with SingVax Pte Ltd and S*Bio Pte
Ltd from Singapore.
Please visit
http://www.biosciencemanagers.com/cfa/news/Asia_Pacific_Life_Science_Forum_2006.pdf
Australian nanobiotech company Starpharma Holdings Limited today
announced the signing of an agreement to acquire US-based Dendritic
Nanotechnologies, Inc. (DNT) for US$6.97m (A$9.36m) through the issue of
Starpharma shares. To view the announcement, please click on the following
link: http://www.starpharma.com
